Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven - Wikidata - wikimedia - TriplyDB

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven

http://www.wikidata.org/entity/Q34589227

about

A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.Modifying Dendritic Cell Activation with Plasmonic Nano Vectors Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.Tumour thermotolerance, a physiological phenomenon involving vessel normalisation Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.Galectin-1 inhibitors and their potential therapeutic applications: a patent review.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.Observations in the Synthesis of the Core of the Antitumor Illudins via an Enyne Ring Closing Metathesis Cascade Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems.Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.Galectins as Molecular Targets for Therapeutic Intervention.Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry

P2860

Q30430457-75F907E4-8AFD-47E9-866B-B011542C4464 Q33906222-46BD4E83-2A6F-40D2-B22E-4207F06921AE Q34564173-EC3E317D-19DA-4F55-8400-3E1ACF6742F6 Q34564225-5836813F-3400-4E78-972B-E77DA1DFAC60 Q34564433-49F406DB-B6DB-4CBF-853A-CED84E428D9D Q34916042-6CFED3B7-234C-4130-9727-A3D0976A1510 Q36082119-4BCB00BD-A080-41CD-B97D-C40833C4D6B6 Q36379734-874AFED8-B67C-4A06-B952-43B214970E48 Q36642433-261AF44F-6ACD-4F68-8BF1-8C5EF36FF851 Q38763827-600D00C4-1DDD-4ADA-8CB4-CA4CAD70E1AD Q39205186-1CB8333B-00FE-4953-B502-BC146681A80C Q41865123-7871088E-CA25-48CD-B435-0CAC35EBC961 Q42590408-01902105-D776-46D3-8BB5-52B52130125B Q48270428-A0849A8E-BAFF-43D3-974F-78764F0CAF8A Q54995893-DB75ABF8-F8C5-44C3-9254-79DCC5004961 Q55283741-89CB8536-706F-4EBC-83E8-75F58D0007DF Q55316400-094184AB-1B7A-4307-8C32-CE44740E9E75 Q57961571-086072E5-5BB8-429B-B50B-89D5783F2519

P2860

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven

http://www.wikidata.org/entity/Q34589227

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@ast

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@en

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@nl

type

label

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@ast

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@en

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@nl

prefLabel

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@ast

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@en

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@nl

P1433

Q34589227-F72FC00D-4422-42A2-8BCD-2F36C3504C27

P1476

Q34589227-B81EFCCE-67EE-435C-B48A-786121064FC5

P2093

Q34589227-05A2D8FD-CF89-474B-AF48-6B35A2679F20

Q34589227-1949236D-DACA-4219-A5AD-EB9A295D1D43

Q34589227-397876D2-E608-4868-B1D3-221D2D3401B6

Q34589227-77DC3EA1-0A2C-4C4A-954E-C977D844C6FE

Q34589227-879F8483-E9DC-4287-81F3-FF1227978C6B

Q34589227-99B7880B-DB11-4BE4-A6B2-FCEF2BAEACE6

Q34589227-B3B468DB-BDE4-443E-BC17-3C025E35B0CB

Q34589227-BA6BFFC7-78B2-4E10-A34E-0D727575ED51

P2860

Q34589227-01006B5F-180A-4152-BA5E-BC13F76E8DEA

Q34589227-237D6CC8-536D-4856-A882-1E58E41BFC5C

Q34589227-2531CA1B-DDCF-402C-9BC9-4D23DE927EC3

Q34589227-27DD9998-57EA-4BE8-8E0B-7F2BA8F7B4B0

Q34589227-302038EE-6ADB-42CA-B439-7F8B58C93C02

Q34589227-330887A6-217B-41C2-9EA1-CB64BAB5ACA9

Q34589227-37B91650-88CE-41C2-8F58-8CB766092ACC

Q34589227-3D722EE9-49D3-42A9-970D-B1154AF882B3

Q34589227-4235D11B-153F-464D-BB0A-ED99D15F4B93

Q34589227-448FB523-51AE-4C28-BB3A-8ACC0A54740C

P304

Q34589227-404D7314-80DD-42ED-A422-9AF2302F121E

P31

Q34589227-52913BE0-0032-4C21-8B22-8783381154EE

P356

Q34589227-F39147A7-8046-40B1-AD64-627BC9126220

P407

Q34589227-59D8A77F-0E76-4D89-B601-A8C6FE5635F1

P433

Q34589227-5DEE815F-EA06-45EE-A688-6AD236C7FD75

P478

Q34589227-A7773022-53A8-4915-9202-80B81E5E9817

P577

Q34589227-92FCB3B9-DFB2-41C6-84AD-57F498FEE329

P5875

Q34589227-274864EF-A21D-4A22-A2B6-8437F859F696

P698

Q34589227-68A5DCEA-CD25-4F99-B726-253479EDCA82

P921

Q34589227-4D3D6E03-0377-472C-9C2E-3967D0D97AFA

P932

Q34589227-F7D080D5-FF5A-448B-88B8-A723E62A11E0

P356

J.CANLET.2008.02.048

P1433

P1476

Ovarian tumor growth regressio ...... the chemotherapeutic irofulven

@en

P2093

Emily S Van Laar

http://www.w3.org/2001/XMLSchema#string

Jeremy Webber

http://www.w3.org/2001/XMLSchema#string

John R MacDonald

http://www.w3.org/2001/XMLSchema#string

Kevin H Mayo

http://www.w3.org/2001/XMLSchema#string

Robert J Griffin

http://www.w3.org/2001/XMLSchema#string

Ruud P M Dings

http://www.w3.org/2001/XMLSchema#string

Stephen J Waters

http://www.w3.org/2001/XMLSchema#string

Yan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities.

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.

Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature

Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

Recent advances in the treatment of epithelial ovarian cancer.

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

Irofulven (MGI Pharma).

P304

270-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANLET.2008.02.048

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

265

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5475052

http://www.w3.org/2001/XMLSchema#string

P698

18378392

http://www.w3.org/2001/XMLSchema#string

P921

P932

3042303

http://www.w3.org/2001/XMLSchema#string